| Literature DB >> 31805647 |
Shirley Cai1,2,3, Deanne K Thompson1,2,4,5, Peter J Anderson1,6, Joseph Yuan-Mou Yang2,4,7,8.
Abstract
Sepsis is commonly experienced by infants born very preterm (<32 weeks gestational age and/or <1500 g birthweight), but the long-term functional outcomes are unclear. The objective of this systematic review was to identify observational studies comparing neurodevelopmental outcomes in very preterm infants who had blood culture-proven neonatal sepsis with those without sepsis. Twenty-four studies were identified, of which 19 used prespecified definitions of neurodevelopmental impairment and five reported neurodevelopmental outcomes as continuous variables. Meta-analysis was conducted using 14 studies with defined neurodevelopmental impairment and demonstrated that very preterm infants with neonatal sepsis were at higher risk of impairments, such as cerebral palsy and neurosensory deficits, compared with infants without sepsis (OR 3.18; 95% CI 2.29-4.41). Substantial heterogeneity existed across the studies (I2 = 83.1, 95% CI 73-89). The five studies that reported outcomes as continuous variables showed no significant difference in cognitive performance between sepsis and non-sepsis groups. Neonatal sepsis in very preterm infants is associated with increased risk of neurodevelopmental disability. Due to the paucity of longitudinal follow-up data beyond 36 months, the long-term cognitive effect of neonatal sepsis in very preterm infants could not be conclusively determined. Effects on the development of minor impairment could not be assessed, due to the small numbers of infants included in the studies.Entities:
Keywords: brain; cognition; development; infant; infection; premature
Year: 2019 PMID: 31805647 PMCID: PMC6956113 DOI: 10.3390/children6120131
Source DB: PubMed Journal: Children (Basel) ISSN: 2227-9067
Figure 1Flow diagram of the study selection process.
Summary of the study design and study population characteristics of all included studies.
| Author | Year | Study Design | Population | Birth Year | No. of Survivors at Follow-Up | Follow-Up Rate | Total No. Followed Up | No. of Confirmed Sepsis | No. of Non-sepsis Comparators | Organism Isolated | Age at Assessment (Months) | Blinding of Outcome Assessors |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
| 1994 | SC, cohort | GA 23–28 | 1983–1986 | 153 | 97% | 149 | 18 | 131 | NS | 52–62 | Yes |
|
| 1998 | SC, case control | BW < 1250 | 1990–1995 | 35 | N/A | N/A | 14 | 21 | Candida | 9–50 | NS |
|
| 2000 | SC, cohort | ELBW | 1988–1996 | 334 | 90% | 299 | 27 | 272 | Candida | 21–24 | NS |
|
| 2000 | SC, cohort | ELBW | 1992–1995 | 241 | 92% | 221 | 109 | 112 | NS | 20 | NS |
|
| 2004 | SC, cohort | GA 23–26 | 1986–2000 | 778 | 87% | 675 | NS | NS | NS | 36–60 | No |
|
| 2004 | MC, cohort | ELBW | 1993–2001 | 7892 | 80% | 6314 | 1922 | 2161 | Shows breakdown | 18–22 | NS |
|
| 2008 | SC, cohort | GA < 30 | 2001–2003 | 204 | 94% | 192 | 64 | 119 | NS | 24 | NS |
|
| 2011 | MC, cohort | VLBW | 2003–2004 | 2847 | 64% | 1826 | 113 | 1714 | NS | 36–42 | NS |
|
| 2011 | SC, cohort | VLBW | 1989–2007 | 967 | N/A | N/A | NS | NS | NS | 18–24 | NS |
|
| 2011 | MC, cohort | GA 24–27 | 2000–2007 | 482 | 77% | 372 | 136 | 236 | Shows breakdown | 18–24 | NS |
|
| 2011 | SC, case-control | GA < 32 or VLBW | 2000–2001 | 50 | N/A | N/A | 32 | 18 | Shows breakdown | 72–108 | NS |
|
| 2013 | MC, cohort | ELBW | 2004–2007 | 1966 | 71% | 1391 | 474 | 917 | Candida and other | 18–22 | NS |
|
| 2013 | SC, case-control | GA < 30 | 1997–2007 | 168 | 90% | 152 | 50 | 102 | GN and Candida | 24 | NS |
|
| 2013 | SC, case control | VLBW | 2008–2009 | 33 | N/A | N/A | 13 | 20 | NS | 18–24 | NS |
|
| 2013 | MC, cohort | GA 22–32 | 1997 | 2277 | 78% | 1769 | 688 | 1081 | NS | 60 | NS |
|
| 2014 | SC, cohort | GA < 29 | 1995–2008 | 383 | 87% | 332 | 105 | 227 | CONS | 30–42 | Yes |
|
| 2014 | SC, cohort | GA < 32 or VLBW | 2003–2010 | 291 | 78% | 226 | 62 | 164 | Shows breakdown | 18–24 | Yes |
|
| 2015 | SC, cohort | VLBW | 1996–1999 | 111 | 55% | 61 | 26 | 35 | NS | 144–180 | NS |
|
| 2016 | SC, cohort | VLBW | 2005–2012 | 200 | 78% | 155 | N/A | N/A | NS | 36–42 | NS |
|
| 2016 | MC, cohort | GA < 29 | 2009–2011 | 2340 | 80% | 1870 | NS | NS | NS | 18–21 | NS |
|
| 2016 | SC, cohort | GA < 32 | 2008–2010 | 100 | N/A | N/A | 17 | 33 | NS | 24, 48 | NS |
|
| 2017 | MC, cohort | GA < 28 | 2002–2004 | 966 | 92% | 889 | 223 | 532 | NS | 120 | Yes |
|
| 2018 | MC, cohort | GA 23–28 | 2007–2012 | 1897 | 80% | 1514 | 526 | 988 | NS | 24–36 | NS |
|
| 2019 | SC, cohort | GA < 32 or VLBW | 2008–2014 | 104 | 87% | 90 | 68 | 22 | Shows breakdown | 24 | Yes |
Abbreviations: SC—single-centre, MC—multicentre, GA—gestational age (weeks), BW—birth weight (grams), ELBW—extremely low birth weight (<1000 g), VLBW—very low birth weight (<1500 g), GN—Gram-negative organisms, CONS—coagulase negative Staphylococci, N/A—not applicable, NS—not specified.
Neurodevelopmental outcome scales used by the included studies and their respective neurodevelopmental impairment definitions.
| Study | Scale Used | NDI Definitions |
|---|---|---|
|
| ||
| Msall [ | McCarthy Scales of Children’s Abilities, Cattell Infant Intelligence Test or the Clinical Linguistic Auditory Milestone Scale (for children with a mental age < 30 months) | One or more of the following: CP defined as early onset, nonprogressive motor and postural delay (hemiplegia, diplegia or quadriplegia) IQ: Mild 52–67, Moderate 36–51, Severe 20–35 on McCarthy instrument Blindness defined as legal blindness or corrected vision worse than 20/200 Deafness defined as bilateral hearing impairment of more than 85 dB |
| Lee [ | BSID-II (<24 months), Stanford–Binet Intelligence Scale, Peabody Developmental Motor Scales | One or more of the following: CP of all types of severity Legal blindness (corrected visual acuity of the better eye, <20/200) Hearing loss (neurosensory hearing loss in the better ear, >30 dB) Cognitive delay (MDI, >3 SD below the mean) |
| Friedman [ | BSID-II | Mild-moderate: mild-moderate CP, moderate cognitive delay (MDI 70–82) |
| Hack [ | BSID-II | One or more of the following: CP (spastic diplegia, hemiplegia, hemiplegia, or quadriplegia), hypertonia, hypotonia and shunt-dependent hydrocephalus Blindness unilateral or bilateral Deafness unilateral or bilateral MDI < 70 |
| Hoekstra [ | BSID-II (<36 mo) | Mild–moderate: isolated muscle tone abnormalities, unilateral blindness, hyperactivity, scores 1–2 SD below mean |
| 3–6 years: Denver Developmental Screening Test, Early Language Milestone Scale, Zimmerman Preschool Articulation Test | Mild–moderate: minor abnormalities, developmental assessments 6–12 months below chronological age | |
| School children: University of Vermont Achenbach Child Behaviour Checklist and the Teacher’s Report form | Mild–moderate: below grade average in >1 subject, but not far below in >1 subject, or had below-normal Achenbach scores | |
| Stoll [ | BSID-II | One or more of the following: CP MDI < 70 or PDI < 70 Bilateral blindness Bilateral hearing impairment |
| Kono [ | KPSD | One or more of the following: CP (nonprogressive CNS disorder characterised by abnormal muscle tone in at least one extremity and abnormal control of movement and posture) Unilateral or bilateral blindness Hearing impairment requiring hearing aids KPSD < 70 or judged by physicians (i.e., ability to say any meaningful words, ability to say own name or age, able to build using several small bricks, able to distinguish size of circles with a diameter of 4 cm and 6 cm) |
| Jang [ | BSID or Denver Developmental Screening Test | One or more of the following: CP (permanent, but no unchanging, disorder of movement and/or posture and of motor function caused by a nonprogressive interference, lesion, or abnormality of the developing immature brain) >6 months delay of motor and/or mental development including cognitive impairment, psychomotor impairment and neurosensory impairment |
| Schlapbach [ | BSID-II, GMFCS | One or more of the following: CP (nonprogressive motor disorder characterised by abnormal tone in at least one extremity and abnormal control of movement and posture) MDI < 70 or PDI < 70 Bilateral blindness Hearing impairment requiring amplification |
| Adams-Chapman [ | BSID-II, BSID-III, GMFCS | BSID-II (Epoch 1) Moderate–severe CP with GMFCS ≥ 2 MDI < 70 or PDI < 70 Bilateral blindness with no functional vision Bilateral amplification for permanent hearing loss Moderate to severe CP with GMFCS ≥ 2 BSID-III cognitive < 70 Visual acuity < 20/200 bilateral Permanent hearing loss that does not permit the child to understand directions of examiner and communicate despite amplification |
| De Haan [ | BSID-II-NL | One or more of the following: CP ± clinical hearing loss or visual handicaps MDI < 85 or PDI < 85 |
| Dilli [ | BSID-II, GMFCS | One or more of the following: Moderate–severe CP MDI < 70, PDI < 70 Bilateral deafness Bilateral blindness |
| Mitha [ | Kaufman Assessment Battery for Children |
CP (at least two of the following: abnormal posture or movement, increased tone, hyperreflexia) MPC < 70 |
| Alshaikh [ | BSID-II, WPPSI-Revised, Stanford–Binet IV | One or more of the following: CP (non-progressive motor impairment characterised by abnormal muscle tone in at least one extremity and decreased range or control of movements) Cognitive delay >2 SD below mean on standardised assessment (WPPSI-Revised, BSID-II or Stanford–Binet IV) Sensorineural hearing loss requiring amplification Visual acuity <20/200 following refractive correction |
| Yang [ | CBCL, “Current Status Survey”, WISC-IV, MINI-KID (for ADHD, anxiety/mood disorders), DSM-IV-TR (for ASD) | “Disabled” = when parents disclosed that the child received a handicap status as issued by the Ministry of the Interior of Taiwan. Handicap is defined as disadvantaged condition, deriving from impairment or disability limiting a person performing a role considered normal in respect of their age, sex and social and cultural factors. |
| Maruyama [ | KPSD | One or more of the following: CP Unilateral or bilateral blindness Severe hearing impairment Developmental delay: DQ < 70 |
| Synnes [ | BSID-III, GMFCS | Severe NDI CP with GMFCS III, IV or V Bayley-III motor composite < 70, cognitive composite < 70, language composite < 70 Hearing aid or cochlear implant Bilateral visual impairment CP with GMFCS I Bayley-III motor composite < 85, cognitive < 85, language composite < 85 Sensorineural/mixed hearing loss Unilateral or bilateral visual impairment |
| Bright [ | GMFCS, DAS-II, OWLS, NEPSY-II, WIAT-III, Manual Ability Classification Test |
Parent-reported legally blind—severe visual impairment Severe auditory impairment—parent-reported child has hearing aids or cochlear plant and/or receives special services for the hearing-impaired |
| Bolisetty [ | BSID-III, GMFCS | Moderate BSID-III 2–3 SD below mean Moderate CP GMFCS level 2 or 3 (able to walk with the assistance of aids) Bilateral deafness (requiring amplification with hearing aids or unilateral/bilateral cochlear implants) BSID-III >3 SD below mean Severe CP GMFCS level 4 or 5 (unable to walk with the assistance of aids) Bilateral blindness (visual acuity of <6/60 in better eye) |
|
| ||
| Shah [ | BSID-II | N/A |
| Van der Ree [ | Bax’ criteria, GMFCS, Movement ABC, WISC-III-NL, NEPSY-II, AVLT, TEA-Ch, ADHD questionnaire, BRIEF, CBCL | N/A |
| Hentges [ | BSID-II | N/A |
| Young [ | At 2 years: BSID-III | N/A |
| Zonnenberg [ | BSID-II, Lexilijst (lexical development questionnaire), CBCL | N/A |
Abbreviations: NDI—neurodevelopmental impairment; CP—cerebral palsy; BSID-II—Bayley Scales of Infant Development, Second Edition; MDI—Mental Development Index; PDI—Psychomotor Development Index; KPSD—Kyoto Scale of Psychological Development; DQ—Development Quotient; GMFCS—Gross Motor Function Classification System; Bayley-III—Bayley Scales of Infant and Toddler Development, Third Edition; MPC—Mental Processing Composite score; WPPSI-Revised—Wechsler Preschool and Primary Scales of Intelligence, Revised; CBCL—Child Behaviour Checklist; WISC-IV—Wechsler Intelligence Scale for Children-IV; MINI-KID—Mini-International Neuropsychiatric Interview for Children and Adolescents; DAS-II—School-Age Differential Ability Scales, Second Edition; OWLS—Oral Written Language Scales; NEPSY-II—Neuropsychological Assessment, Second Edition; WIAT-III—Wechsler Individual Achievement Test, Third Edition; M-ABC—Movement Assessment Battery for Children; WISC-III—Wechsler Intelligence Scale for Children, Third edition; AVLT—Rey’s Auditory Verbal Learning Test; TEA-Ch—Test of Everyday Attention for Children; BRIEF—Behavior Rating Inventory of Executive Function; WPPSI-III—Wechsler Preschool and Primary Scales of Intelligence, Third edition; CELF-2—Clinical Evaluation of Language Fundamentals—Preschool, Second Edition; WASI—Wechsler Abbreviated Scale of Intelligence; M-ABC2—Movement Assessment Battery for Children, Second Edition; CELF-4—Clinical Evaluation of Language Fundamentals, Fourth Edition; CLI—Core Language Index; WMTB-C—Working Memory Test Battery for Children; SD—standard deviation(s); N/A—not applicable.
Figure 2Assessment of risk of bias of the 24 included studies. The risk of bias was assessed using a modified version of the Cochrane Collaboration’s tool for assessing risk of bias; see Table S2.
Summary of the 19 studies with reported dichotomised neurodevelopmental outcomes.
| Number of Infants with NDI | ||||
|---|---|---|---|---|
| Study | Sepsis Group | No Sepsis Group | Attrition Rate | Comments |
|
| 9/18 (50%) | 22/131 (17%) | 3% | N/A |
|
| 4/14 (29%) | 3/21 (14%) | N/A | N/A |
|
| 11/27 (41%) | 32/272 (12%) | 10% | N/A |
|
| 43/93 (46%) | 62/112 (55%) | 8% | N/A |
| NS | NS | 13% | At 47.5 months (range 36–60), there was no statistically significant association between primary or secondary sepsis and NDI. | |
|
| 861/1778 (48%) | 576/1976 (29%) | 20% | N/A |
| NS | NS | 36% | At 36–42 months, there was an association between sepsis and cerebral palsy or death (OR 2.6, 95% CI 1.4–4.8) as well as sepsis and NDI or death (OR 2.8, 95% CI 1.6–4.8). | |
| NS | NS | N/A | At 18–24 months, univariate analysis showed weak association between sepsis and cerebral palsy (OR 1.653, 95% CI 0.849–3.215). | |
|
| 46/134 (34%) | 55/235 (23%) | 23% | N/A |
|
| 148/474 (31%) | 153/917 (17%) | 16% | N/A |
|
| 28/50 (56%) | 16/102 (17%) | 10% | N/A |
|
| 8/13 (62%) | 4/20 (20%) | N/A | N/A |
|
| 84/643 (14%) | 73/1126 (6%) | 22% | N/A |
|
| 26/105 (25%) | 34/227 (15%) | 13% | N/A |
|
| 13/26 (50%) | 7/35 (20%) | 45% | N/A |
|
| 3/4 (75%) | 37/153 (24%) | 28% | N/A |
| NS | NS | 20% | At 18–21 months, there was significant association between sepsis and significant NDI (OR 1.50, 95% CI 1.05–1.86), but no information was reported on association between sepsis and NDI. | |
| NS | NS | 8% | At 10 years of age, children who had confirmed bacteraemia were associated with lower z-scores in verbal and nonverbal IQ, oral expression, academic achievement, executive function and visual impairment. They were also more likely to have visual and auditory impairment but not motor deficits. After adjusting for IQ, many of these associations were lost. | |
|
| 138/526 (26%) | 29/988 (3%) | 20% | N/A |
|
| 1422/3905 (36%) | 1103/6315 (17%) | Median: 18% | |
#: studies did not report absolute numbers for NDI for each study group. NS—not specified; N/A—not applicable.
Figure 3Forest plot showing the results of random effects meta-analysis of the 14 studies comparing neurodevelopmental outcomes in very premature infants with and without neonatal sepsis exposure (Outcome: number of participants with neurodevelopmental impairment). NDI—neurodevelopmental impairment; OR—odds ratio; CI—confidence interval.
Figure 4Contour-enhanced funnel plot of the 14 studies with reported dichotomised neurodevelopmental outcomes.
Figure 5Forest plot of the subanalysis of studies which had a follow-up duration of 36 months or greater. The plot shows the results of random effects meta-analysis of the four studies comparing neurodevelopmental outcomes in very premature infants with and without neonatal sepsis exposure (Outcome: number of participants with neurodevelopmental impairment).
Summary of the five studies with reported continuous neurodevelopmental outcomes.
| Study | Assessment Tool | Sepsis Group | Non-sepsis Group | Attrition Rate | Comments |
|---|---|---|---|---|---|
| Mean (SD) | Mean (SD) | ||||
| Shah [ | MDI (BSID-II) | 79.7 (21.2) | 86.5 (18.7) | 6% | N/A |
| PDI (BSID-II) | 84.2 (21.4) | 89.9 (14.5) | |||
| Van der Ree [ | Movement ABC Total (M-ABC2)—raw score | 13 (10) | 8 (6) | N/A | N/A |
| Total intelligence (WISC-II)—IQ | 89 (13) | 98 (8) | |||
| Total behavioural problems (CBCL)—t-scores | 53 (12) | 56 (9) | |||
| Hentges [ | MDI (BSID-II) | 85.9 (10.8) | 86.1 (11.59) | 22% | N/A |
| PDI (BSID-II) | 89.8 (13.3) | 91.7 (14.02) | |||
| Young [ | At 2 years: BSID-III | NS | NS | N/A | Sepsis was not significant with 2-year or 4-year cognitive measures, but significant with 4-year behavioural measures. |
| At 4 years: WPPI-III, CLEF-2, Beery–Buktenica Test of Visual Motor Integration, the Behaviour Assessment System for Children Parent Rating Scales, Behavioural Rating Inventory of Executive Functioning – Preschool | |||||
| Zonnenberg [ | MDI (BSID-II) | 100 (9.0) | 98 (13.9) | 23% | N/A |
| PDI (BSID-II) | 100 (9.4) | 99 (12.3) | |||
| Lexiquotient (Lexilijst) | 91 (16.1) | 88 (18.2) | |||
| Total behavioural score (CBCL) | 26 (14.9) | 30 (21.2) | |||
| Total internalising score (CBCL) | 5 (4.3) | 8 (7.9) | |||
| Total externalising score (CBCL) | 12 (7.5) | 12 (7.6) | |||
| Median: 22% |
#: Studies did not report group mean and SD for sepsis and non-sepsis group. NS—not specified.